AFT Pharmaceuticals Limited (NZE:AFT)
New Zealand · Delayed Price · Currency is NZD 3.980
+0.050 (1.27%)
Jun 2, 2026, 11:03 AM NZST
AFT Pharmaceuticals Income Statement
Financials in millions NZD. Fiscal year is April - March.
Millions NZD. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 254.71 | 208.02 | 195.41 | 156.64 | 130.31 | |
Revenue Growth (YoY) | 22.44% | 6.45% | 24.75% | 20.20% | 15.21% |
Cost of Revenue | 144.15 | 116.31 | 107.14 | 83.66 | 68.54 |
Gross Profit | 110.55 | 91.71 | 88.27 | 72.98 | 61.78 |
Selling, General & Admin | 75.85 | 65.05 | 58.09 | 49.4 | 37.99 |
Research & Development | 9.84 | 9.77 | 6.47 | 3.91 | 3.62 |
Other Operating Expenses | 0.41 | -0.75 | -0.53 | - | -0.23 |
Operating Expenses | 86.11 | 74.07 | 64.04 | 53.31 | 41.39 |
Operating Income | 24.45 | 17.65 | 24.24 | 19.67 | 20.39 |
Interest Expense | -2.49 | -2.82 | -3.69 | -2.87 | -2.44 |
Interest & Investment Income | 0.01 | 0.03 | 0.07 | 0.01 | 0 |
Currency Exchange Gain (Loss) | 0.76 | 0.73 | 1.11 | -3.14 | 0.64 |
Other Non Operating Income (Expenses) | -0.85 | 0.46 | 0.3 | 2.13 | 0.09 |
EBT Excluding Unusual Items | 21.87 | 16.03 | 22.02 | 15.8 | 18.69 |
Pretax Income | 21.87 | 16.03 | 22.02 | 15.8 | 18.69 |
Income Tax Expense | 7.8 | 4.63 | 6.41 | 5.15 | -1.16 |
Earnings From Continuing Operations | 14.08 | 11.4 | 15.61 | 10.65 | 19.85 |
Minority Interest in Earnings | 0.65 | 0.56 | - | - | - |
Net Income | 14.73 | 11.96 | 15.61 | 10.65 | 19.85 |
Net Income to Common | 14.73 | 11.96 | 15.61 | 10.65 | 19.85 |
Net Income Growth | 23.14% | -23.36% | 46.51% | -46.32% | 155.05% |
Shares Outstanding (Basic) | 105 | 105 | 105 | 105 | 105 |
Shares Outstanding (Diluted) | 105 | 105 | 105 | 105 | 105 |
Shares Change (YoY) | - | - | 0.02% | 0.16% | 1.34% |
EPS (Basic) | 0.14 | 0.11 | 0.15 | 0.10 | 0.19 |
EPS (Diluted) | 0.14 | 0.11 | 0.15 | 0.10 | 0.19 |
EPS Growth | 27.27% | -26.10% | 46.48% | -46.41% | 168.07% |
Free Cash Flow | -9.66 | 12.9 | 28.75 | 11.43 | 13.82 |
Free Cash Flow Per Share | -0.09 | 0.12 | 0.27 | 0.11 | 0.13 |
Dividend Per Share | 0.025 | 0.018 | 0.016 | 0.011 | - |
Dividend Growth | 38.89% | 12.50% | 45.45% | - | - |
Gross Margin | 43.40% | 44.09% | 45.17% | 46.59% | 47.41% |
Operating Margin | 9.60% | 8.48% | 12.40% | 12.56% | 15.65% |
Profit Margin | 5.78% | 5.75% | 7.99% | 6.80% | 15.23% |
Free Cash Flow Margin | -3.79% | 6.20% | 14.71% | 7.30% | 10.61% |
EBITDA | 24.87 | 18.02 | 24.63 | 19.88 | 20.67 |
EBITDA Margin | 9.76% | 8.66% | 12.61% | 12.69% | 15.86% |
D&A For EBITDA | 0.42 | 0.37 | 0.4 | 0.21 | 0.28 |
EBIT | 24.45 | 17.65 | 24.24 | 19.67 | 20.39 |
EBIT Margin | 9.60% | 8.48% | 12.40% | 12.56% | 15.65% |
Effective Tax Rate | 35.64% | 28.90% | 29.11% | 32.56% | - |